Updates are available Correction dated 2020-03-16
Click to view Correction: https://doi.org/10.1007/s10549-020-05594-6
-
Authors
Gonzalez, Thomas L.
Hancock, Molly
Sun, Siqi
Gersch, Christina L.
Larios, Jose M.
David, Wadie
Hu, Jiantao
Hayes, Daniel F.
Wang, Shaomeng
Rae, James M. http://orcid.org/0000-0002-3412-8219
-
Funding
Funding for this research was provided by:
National Institute of Environmental Health Sciences (T32ES007062)
Breast Cancer Research Foundation (N003173)
University of Michigan Rogel Cancer Center Breast Strategic Fund
- License Information
-
More Information
Article History
Received: 9 October 2019
Accepted: 3 February 2020
First Online: 17 February 2020
Change Date: 16 March 2020
Change Type: Correction
Change Details: In the original publication of the article, the spelling of the sixth author’s given name was incorrect. The corrected author name should read as “Wadie David”. The original article has been corrected.
Compliance with ethical standards
:
: The University of Michigan has filed a patent application on ERD-148 and its related ER degraders. S.W. and J.H. are co-inventors on the patent application, which has been licensed to Oncopia Therapeutics, Inc. S.W. is a co-founder of Oncopia and a paid consultant. S.W. and the University of Michigan own stock in Oncopia. The University of Michigan has received a research contract from Oncopia for which S.W. serves as the principal investigator.
: This article does not contain any studies with human participants or animals performed by any of the authors.
